SCHEMBL464734

SCHEMBL464734

NS(=O)(=O)c1cccc2c1OCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
EPHB4 P54760 1/20 0.40
CA2 P00918 6/20 0.40
CA9 Q16790 5/20 0.40
CA1 P00915 5/20 0.40
CA12 O43570 3/20 0.40
CA6 P23280 3/20 0.40
CA5A P35218 2/20 0.40
CA7 P43166 2/20 0.40
CA5B Q9Y2D0 2/20 0.40
PTGS1 P23219 2/20 0.40
PTGS2 P35354 2/20 0.40
MAOB P27338 1/20 0.40
CA4 P22748 2/20 0.39
CYP2C9 P11712 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CHRM1 P11229 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10664550 0.85 ACLY (0.44) CA2CA9CA1CA12CA6
SCHEMBL464729 0.84 PTGS1 (0.43) PKMTSHREPHB4CA2CA9
SCHEMBL464723 0.83 MGAM (0.37) PKMEPHB4CA2CA9CA1
SCHEMBL464724 0.83 ALDH1A1 (0.39) EPHB4CA2CA9CA1CA12
SCHEMBL464740 0.82 PTGS2 (0.36) TSHREPHB4CA2CA9CA12
SCHEMBL464779 0.81 GSK3B (0.42) ABCG2PKMTSHRPTGS1PTGS2
SCHEMBL4749803 0.81 MAOB (0.43) ABCG2PKMTSHRMAOBCHRM1
SCHEMBL464814 0.80 CA12 (0.40) TSHREPHB4CA2CA9CA1
SCHEMBL464731 0.79 MGAM (0.37) EPHB4PTGS1PTGS2MAOBCHRM1
Hydrochloric Acid SCHEMBL5308121 0.73 CA2 (0.36) ABCG2PKMTSHRCA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
EP-1686113-B1 Inhibitors of aspartyl protease VERTEX PHARMA (US) 2011-11-23 EP disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1686113-A1 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-08-02 EP disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed
US-4746358-A PLANT GROWTH REGULATORS, HERBICIDES; N-TRIAZINYL-AMINOCARBONYL -1,4-BENZODIOXANESULFONAMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-05-24 US disclosed
US-4659368-A HERBICIDES; PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-04-21 US disclosed
EP-0099339-B1 CONDENSED N-PHENYLSULFONYL-N'-PYRIMIDINYL AND TRIAZINYL UREA CIBA-GEIGY AG (CH) 1987-01-07 EP disclosed
US-4634465-A PRE- AND POSTEMERGENCE HERBICIDES CIBA-GEIGY CORPORATION (US) 1987-01-06 US disclosed
US-4595407-A Triazinyl-amino-carbonyl-1,3-benzohetero- or -1,4-benzohetero-sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-06-17 US disclosed
US-4502882-A HERBICIDES, PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-03-05 US disclosed
EP-0099339-A2 Condensed N-phenylsulfonyl-N'-pyrimidinyl and triazinyl urea CIBA-GEIGY AG (CH) 1984-01-25 EP disclosed
EP-0082681-A2 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 ABCG2 328/4885PKM 2752/4885TSHR 4851/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 ABCG2 328/4885PKM 2752/4885TSHR 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.